Back to All Research and Clinical Studies
Epilepsy, Gastrointestinal Health

Modulation of Gut Microbiome and Metabolome as One of the Potential Mechanisms of Ketogenic Diet Effect in the Treatment of Epilepsy 

Research Summary Modulation of Gut Microbiome and Metabolome as One of the Potential Mechanisms of Ketogenic Diet Effect in the Treatment of Epilepsy

The ketogenic diet (KD) has been used for over a century to treat epilepsy, particularly in children with drug-resistant epilepsy (DRE). While its seizure-reducing efficacy is well established, its underlying mechanisms remain only partly understood.

Emerging evidence points to modulation of the gut microbiome and metabolome as a contributing factor. Individuals with epilepsy, especially those with DRE, often show altered gut microbial profiles, which have been linked to seizure frequency, treatment response, and gastrointestinal comorbidities.

Clinical and preclinical studies demonstrate that KD produces measurable shifts in gut microbiota. Common changes include increases in Bacteroides and Blautia and decreases in Bifidobacterium, Actinobacteria, and certain Proteobacteria. Although microbial diversity often declines during KD, this is not consistently associated with adverse inflammatory or gastrointestinal effects.

KD also alters microbial metabolite production, including short-chain fatty acids (SCFA) such as acetate and butyrate, and tryptophan-derived compounds such as kynurenic acid. Researchers have also reported reductions in systemic and intestinal inflammatory markers, including TNF and IL-17, and lower fecal genotoxicity. Specific bacterial species (e.g., Bifidobacterium longum, Eggerthella lenta, Gordonibacter pamelaeae) have been associated with greater seizure reduction during KD, while others (e.g., Alistipes shahii, Eubacterium rectale) are more common in non-responders. These associations support the potential of microbiota profiles as predictive biomarkers of KD response.

Mechanistically, KD may support seizure control through several gut-mediated pathways:

  • Microbial rebalancing: Shifts the gut microbiome toward a more favorable composition, often with increased Bacteroidetes and reduced pro-inflammatory bacteria.
  • Neurotransmitter modulation: Increases gut bacteria involved in GABA and serotonin production, enhancing inhibitory signaling in the brain.
  • Anti-inflammatory effects: Reduces intestinal and systemic inflammation by lowering cytokine levels and suppressing inflammasome activity (e.g., NLRP3).
  • Tryptophan metabolism: Promotes the conversion of tryptophan into neuroprotective compounds such as kynurenic acid, rather than neurotoxic metabolites.
  • SCFA modulation: Alters short-chain fatty acid production, which may affect gut barrier function and gut–brain signaling.
  • Microbial predictors of response: Certain bacterial species are consistently linked to clinical improvement and may guide personalized therapeutic strategies.

Evidence suggests that gut microbiota and their metabolites may contribute to the antiepileptic effects of the ketogenic diet. These insights could explain variability in treatment response and support microbiome-informed strategies, such as probiotics or diagnostics. Further research is needed to confirm mechanisms, identify predictive markers, and evaluate long-term effects on gut and metabolic health.

Source:

Nutrients img Source: Nutrients

img
  • title-icon Study Title:
    Modulation of Gut Microbiome and Metabolome as One of the Potential Mechanisms of Ketogenic Diet Effect in the Treatment of Epilepsy 
  • source-icon Source: https://doi.org/10.3390/nu18010031
  • calendar-icon Publication Date:
    December 21, 2025
  • author-icon Study Authors:
    Kowalcze K, Dyńka D, Klus W, Dudzińska M, Paziewska A
Tags:
DRE Probiotics GABA Tryptophan SCFA Short-Chain Fatty Acids Metabolome Gut Microbiome Keto Drug-resistant epilepsy Seizures Microbiome Gut health ketogenic diet Epilepsy Neuroinflammation Gut-brain axis Pediatric epilepsy Inflammation